BTIG analyst Ryan Zimmerman has maintained their neutral stance on PRCT stock, giving a Hold rating on September 9.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ryan Zimmerman has given his Hold rating due to a combination of factors impacting PROCEPT BioRobotics. The company’s stock has seen a significant decline, and despite the ability to exceed its own guidance, the results have not met expectations. The introduction of a new CEO presents an opportunity for change, but several challenges remain.
Utilization rates need improvement, as the current growth does not align with future guidance expectations. Additionally, the Street’s projections for FY26 sales appear optimistic, with limited room for upside unless new growth avenues are discovered. Operating expenses have also been a concern, growing at a rate that challenges the path to profitability. While the valuation is more attractive now, it aligns with industry peers, and concerns about utilization and sales persist, justifying the Hold rating.
In another report released on September 9, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $39.00 price target.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRCT in relation to earlier this year.